United Therapeutics diskutieren
United Therapeutics
WKN: 923818 / Symbol: UTHR / Name: Utd Therapeut / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
421,00 €
0,87 %
United Therapeutics Co. (NASDAQ: UTHR) had its price target lowered by analysts at JPMorgan Chase & Co. from $355.00 to $350.00. They now have an "overweight" rating on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for UTHR provided by MarketBeat
United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $425.00 price target on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics Co. (NASDAQ: UTHR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $405.00 price target on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics Corporation (NASDAQ: UTHR) had its price target lowered by analysts at UBS Group AG from $410.00 to $385.00. They now have a "buy" rating on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics Corporation (NASDAQ: UTHR) had its price target lowered by analysts at JPMorgan Chase & Co. from $350.00 to $330.00. They now have an "overweight" rating on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics Corporation (NASDAQ: UTHR) had its price target raised by analysts at UBS Group AG from $385.00 to $415.00. They now have a "buy" rating on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics Corporation (NASDAQ: UTHR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at Jefferies Financial Group Inc. from $432.00 to $564.00. They now have a "buy" rating on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at UBS Group AG from $415.00 to $560.00. They now have a "buy" rating on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $510.00 to $575.00. They now have an "outperform" rating on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at Cantor Fitzgerald from $405.00 to $525.00. They now have an "overweight" rating on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) is now covered by analysts at Royal Bank Of Canada. They set an "outperform" rating and a $569.00 price target on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at UBS Group AG. They now have a $580.00 price target on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) is now covered by analysts at Wells Fargo & Company. They set an "underweight" rating and a $414.00 price target on the stock.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at UBS Group AG from $580.00 to $600.00. They now have a "buy" rating on the stock.
Ratings data for UTHR provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Hasbro Inc. diskutieren